Researchers found a new variant of mesothelioma associated with inherited germline BAP1 mutations, which are less aggressive and may respond to therapy. These patients also develop multiple tumors and require early cancer detection screening.
A multidisciplinary guideline panel has determined that guided-bronchoscopy sampling provides tissue of comparable adequacy to percutaneous biopsy for comprehensive biomarker testing, while delivering a superior safety profile. Modern navigational bronchoscopy offers a safer path to molecular insights in lung cancer care.
The IASLC and LCRF have awarded a $2.5 million team science grant to Dr. David Barbie's research team to develop an immune-based approach to target drug-resistant lung cancer cells. The project aims to harness the body's immune system to eliminate persister cells, which contribute to disease progression.
Recent studies from Asia indicate that low-radiation dose computed tomography screening is more effective in detecting cancers in those with a family history of lung cancer, but the benefits are uncertain for never-smokers. The authors advocate for more rigorous research to understand the benefits and harms of screening this population.
The IASLC Early Detection & Screening Committee published a perspective outlining key components of LDCT screening regimens. The report emphasizes the need for data-driven management systems, quality assurance assessments, and multi-disciplinary clinical management to maximize benefits of early detection and treatment.
A study published in the Journal of Thoracic Oncology found that adopting a lung nodule program can increase early lung cancer detection for patients not eligible for traditional screening. The study revealed significant differences in stage at diagnosis and overall survival rates between young, elderly, and screened cohorts.
A study published in Journal of Thoracic Oncology found that Australian patients with mesothelioma experienced higher levels of toxicity on the CheckMate743 regimen compared to clinical trial results. The study suggests combination immunotherapy may have poorer survival outcomes and appears more toxic in real-world practice.
A study found that over half of English NSCLC patients living in low-socio-economic areas did not receive new anti-cancer therapies, despite having access to free treatment through the National Health Service. The researchers examined data from 90,785 patients diagnosed between 2012 and 2017.
A study published in the Journal of Thoracic Oncology suggests that expanding low-dose CT screening eligibility criteria can increase access to screening for women and Black persons. The research found that widening eligibility guidelines reduced smoking exposure criteria increased lung cancer diagnoses among these groups.
A multicenter cohort study found that lung cancer screening increased the percentage of Stage I cases detected by 8.4% and reduced the percentage of Stage IV cases by 6.6%. The study suggests that implementation of screening achieves the desired effect of identifying early-stage lung cancers without resulting in overdiagnosis.
Researchers from Vancouver, British Columbia found a significant association between cumulative three-year versus 20-year exposure to air pollution and the risk of developing lung cancer in women who have never smoked. The study showed that even a 3-year exposure significantly underestimates lifetime exposure to PM2.5 prior to diagnosis.
The POSEIDON trial found that patients with metastatic non-small cell lung cancer who received a combined therapy of tremelimumab, durvalumab and chemotherapy experienced longer overall survival compared to those who received chemotherapy alone. KRAS/STK11/KEAP1 mutations did not impact the benefit of the triplet regimen.
A study published at the IASLC 2022 World Conference on Lung Cancer found that robotic-assisted lobectomy for early-stage lung cancer yields better patient-reported health-related quality of life measures compared to video-assisted lobectomy. The procedure was also associated with superior lymph node sampling.
A study by LUNGevity Foundation found that informed consent forms for lung cancer clinical trials are often too complex, leading to patient overwhelm. The researchers proposed a tri-fold template addendum to provide patients with key information relevant to their participation.
A new nomogram has been developed to assess lung cancer risk in female non-smokers in China, using data from 151,834 patients. The model identified five independent risk factors, including age, chronic respiratory disease, and menopause, and showed good predictive discrimination.
The KEYNOTE-604 study shows that pembrolizumab-based combination with etoposide and platinum significantly improves progression-free survival and overall survival in patients with previously untreated ES-SCLC. Long-term follow-up data also reveal durable responses and manageable safety profiles.
A large international trial found that sub-lobar surgery is non-inferior to lobectomy for patients with peripheral non-small cell lung cancer. The study, which enrolled 1,080 patients, showed similar disease-free survival rates between the two groups.
The IMpower010 trial showed an overall survival trend in favor of atezolizumab in the PD-L1 TC ≥1% stage II-IIIA population, with a clinically meaningful improvement observed across most subgroups. The study found no separation for the ITT population or all-randomized, stage II–IIIA populations.
The DOLPHIN Study reports a high progression-free survival rate of 72.1% and an overall response rate of 90.9% for patients with unresectable locally advanced NSCLC treated with durvalumab plus concurrent radiotherapy.
A randomized phase II trial demonstrated improved 18-month progression-free survival with nivolumab alone or combined with ipilimumab compared to historical controls. The combination of nivolumab and ipilimumab resulted in a higher incidence of treatment-related adverse events, but consistent with prior reports.
A UK-based smoking cessation program, YESS, reported a 30% abstinence rate among patients with lung cancer who participated in a personalized support program. The study found that women achieved higher quit rates compared to men, highlighting the need for continued support.
The NADIM II trial demonstrates the efficacy of neoadjuvant chemoimmunotherapy in patients with resectable stage IIIA NSCLC, with improved progression-free survival and overall survival rates seen with nivolumab plus chemotherapy. Patients with positive PD-L1 expression showed enhanced benefits.
A Phase 2 study demonstrated the accuracy of lung cancer gene panel testing using cytological specimens, with a success rate of 100% and sufficient yield for analysis. The extracted nucleic acid quality was also adequate for panel analysis, enabling the detection of gene mutations in 68.1% of cases.
A study analyzing surgical tissue samples from patients with stage IIIA NSCLC found that high AKT expression and activated dendritic cells were associated with lower progression-free survival and overall survival. The immune expression signature identified could help follow-up and therapeutic management of high-risk patients.
Combining sotorasib with pembrolizumab or atezolizumab demonstrated durable clinical activity, lower treatment-related adverse events, and improved overall survival in patients with advanced KRAS p.G12C NSCLC. The study showed a higher incidence of grade 3-4 adverse events initially, but these effects may be mitigated by dose reduction.
The NELSON Trial demonstrated a 24% reduction in lung cancer mortality with low-dose CT screening, compared to the 20% found in the NLST. The new protocol used in NELSON showed improved sensitivity for early-stage cancers, increasing the benefits of lung cancer screening while reducing unnecessary follow-up procedures.
A recent study found that younger patients with lung cancer are more likely to be diagnosed at later stages, highlighting the need for strategies to increase early detection among younger adults. In contrast, older patients have seen improvements in earlier stage diagnoses since the onset of lung cancer screening.
Research presented at the IASLC World Conference on Lung Cancer 2022 found that increased utilization of Stereotactic Body Radiotherapy (SBRT) has decreased treatment disparities for early-stage non-small cell lung cancer (NSCLC). The study showed a significant increase in the proportion of patients receiving definitive treatment, with...
The IASLC Early Detection and Screening Committee report outlines the challenges of implementing lung cancer screening in low- and middle-income countries. The committee emphasizes the need for evidence-based guidelines, considering regional specificities and population-specific risk factors.
A budget impact analysis shows that implementing the NELSON screening model in 28 European countries could prevent over 18,000 premature lung cancer deaths. The model estimates a total budget impact of approximately €937 million if half of the eligible population is screened.
A phase 3 trial showed sugemalimab improved progression-free survival (PFS) by 69% compared to placebo, with a median PFS of 10.5 months. Overall survival (OS) data also suggested a trend towards benefit favoring sugemalimab.
A study presented at the IASLC World Conference on Lung Cancer 2022 found four molecular subtypes of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping, each with distinct clinical characteristics and responses to treatment.
Researchers found that second primary lung cancer occurs in approximately 4% of lung cancer patients, with a higher rate of up to 8% among those undergoing surgery for early-stage disease. The study also revealed variations in incidence rates by treatment type and stage.
A new study published in the Journal of Thoracic Oncology found that cytisine, a plant-based alkaloid, is a safe and effective smoking cessation therapy. The study showed a 32.1% quit rate for participants taking cytisine compared to 7.3% for those receiving a placebo.
A new study found that COVID-19 vaccines are safe and effective for patients treated for lung cancer with immune checkpoint inhibitors. However, the vaccine's immunogenicity was lower in these patients, raising concerns that require further evaluation.
The COVID-19 pandemic significantly impacted lung cancer clinical trial enrollment, with a 14% decline between 2019 and 2020. Patient-specific challenges included fear of infection, transportation issues, and willingness to visit sites.
A recent study by TERAVOLT identified seven major determinants of death from SARS-CoV-2 infection in patients with thoracic malignancies, including poor ECOG-PS and laboratory confirmed COVID-19 diagnosis. The study found a high all-cause case fatality rate of 24.2% among patients with COVID-19 and thoracic cancer.
A meta-analysis of published research found that patients with lung cancer who quit smoking after diagnosis have significantly improved overall survival. The study suggests treating physicians should educate patients about the benefits of quitting and provide necessary support.
A new study found that SARS-CoV2 vaccines are safe and effective in patients with thoracic cancer, with an 88% immunization rate after a third dose. The study also showed that older age, chemotherapy, and corticosteroid treatment were associated with lower immunization rates.
Researchers found that pre-treatment circulating tumor DNA (ctDNA) levels can accurately predict long-term survival in non-small cell lung cancer (NSCLC) patients. Patients with low ctDNA levels had significantly improved progression-free survival and overall survival compared to those with high levels.
A new study suggests that age does not negatively impact on survival benefit from immune checkpoint inhibitors in elderly patients with stage IV NSCLC. Patients aged 75 and older showed a significant survival benefit from ICIs compared to younger patients.
According to a survey, nearly two-thirds of thoracic oncologists adopted telehealth tools for the first time during the pandemic. The top advantages were continuity of care and maintaining patient contact, while barriers included lack of resources and regulatory limitations.
Research presented at the IASLC 2021 World Conference on Lung Cancer found that neoadjuvant cisplatin and pemetrexed plus atezolizumab followed by surgical resection and maintenance atezolizumab met safety criteria for patients with resectable pleural mesothelioma. Sixty percent of eligible patients proceeded to maintenance therapy.
A meta-analysis of the UKLS trial and nine previous trials found that low-dose CT (LDCT) screening for lung cancer reduces mortality by 16%, with a stronger benefit seen in the three to six years after randomization. This evidence supports the implementation of long-term lung cancer screening programs internationally.
A study of 2,804 patients found significant variability in access to care for malignant pleural mesothelioma treatment. Patients who underwent surgery had better survival outcomes, with a positive association between multimodality treatment and income levels.
A recent study found that patients with lung cancer are more likely to feel anxious and experience treatment delays due to the COVID-19 pandemic. The research, which analyzed data from 548 patients in Mexico, also discovered that depression and stress were associated with longer delays in treatment.
The IASLC molecular subcommittee has accumulated molecular biomarker data to complement TNM-based prognostication in lung cancer. The dataset includes 64,434 cases from 2010-2019 and 14 countries, with EGFR being the most common biomarker.
Treatment with atezolizumab plus carboplatin and pemetrexed was safe and yielded promising brain progression-free survival rates of 60% in patients with nonsquamous non-small cell lung cancer with untreated brain metastases. The combination also showed systemic responses in 47.5% of patients.
A study analyzed open and closed insurance claims to assess practice behavior changes after durvalumab approval. The results showed a low rate of durvalumab utilization, with higher rates in patients over 65 and treated in the Midwest.
A mixed-methods survey of US-based oncology clinicians reveals disparities in biomarker testing use, with academic clinicians more likely to use it. Clinicians express need for education on financial resources, practical applications, and coordinating multidisciplinary care.